This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 2 of 573

The Disgusting Reaction to Ebola Patient's Death by Tekmira, Chimerix Traders

By Adam Feuerstein

Tekmira shares surge after Thomas Duncan's death announced.

11:33AM 10/08/14

Arrowhead Research Sinks on Disappointing Hepatitis B Drug Data

By Adam Feuerstein

In an ongoing phase II study, ARC-520 dosed at 2 mg/kg induced a 0.3 log reduction in HBsAG, a measure of the presence of hepatitis B virus in the body.

10:38AM 10/08/14

Why Northwest Bio Is Shunned by Savvy Health Care Investors

By Adam Feuerstein

If Northwest Bio's cancer vaccines -- DCVax-L and DCVax Direct -- are so promising, hedge funds should be falling over themselves to own the stock, not short it.

07:43AM 10/08/14

It's True, Small-Cap Biotech Stocks Are Acting Badly These Days

By Adam Feuerstein

For the past three months, small-cap biotech stocks have been underperforming the broader market.

11:39AM 10/07/14

Alcobra ADHD Drug Fails Key Study Except When Patients Removed From Analysis

By Adam Feuerstein

Treatment with an experimental formulation of vitamin B6 known as MDX failed to improve the symptoms of attention-deficit hyperactivity disorder compared to placebo.

10:08AM 10/06/14

Sunesis Drug for Elderly Blood Cancer Patients Fails Phase III Study

By Adam Feuerstein

Sunesis' experimental drug vosaroxin did not extend survival of elderly patients with advanced acute myeloid leukemia compared to a placebo.

07:00AM 10/06/14

Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

09:41AM 10/03/14

Why You Should Stay Away From the Ebola Frenzy in Biotech Stocks

By Adam Feuerstein

Ebola lands in Texas, so expect some crazy volatility Wednesday in biotech and drug stocks.

10:08AM 10/01/14

Shkreli's Inability to Focus, Immaturity Cost Him Retrophin CEO Job

By Adam Feuerstein

Martin is super smart and will be a great asset somewhere, but he is not a CEO. I wish him the best.

05:53PM 09/30/14

Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax

By Adam Feuerstein

What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?

09:49AM 09/30/14

Page 2 of 573

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,273.76 -106.65 -0.65%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs